INVEX THERAPEUTICS

Invex Therapeutics (ASX:IXC) is a biopharmaceutical drug development Company seeking to develop efficacious treatments for neurological conditions resulting from raised intracranial pressure (ICP). ICP is a serious issue in a range of neurological conditions, including idiopathic intracranial hypertension, traumatic brain injury or acute stroke... Invex is focused on research and development centered around understanding and defining the mechanisms that regulate pressure in the brain and in particular the repurposing of an already approved drug, Exenatide, to reduce ICP and address a significant unmet medical need. Invex has trademarked its repurposed Exenatide as Presendin™... Invex Therapeutics Limited (ASX:IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke..

Also known as: Invex, Invex Therapeutics Limited, Invex Therapeutics Ltd

Primary location: Perth